Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for PMN310 in Neurodegenerative disease, Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
PRECISE-AD trial. 11/20/23- Dosed first patient. 3/31/25- Dosed first participant. 7/21/25- Granted Fast Track designation. 9/3/25- Received DSMB approval to advance DE cohort. Report 6mt interim data in Q2 2026 and final 12mt data in Q4 2026. 11/12/25:- PRECISE-AD is over 85% enrolled with cohorts 1 and 2 complete and cohort 3 enrollment expected to finish by year-end 2025. Program remains on track to deliver 6-month interim data in Q2 2026 and 12-month topline data in Q4 2026. 12/18/25:- PRECISE-AD enrollment completed (144 patients); favorable safety with no treatment-related SAEs; interim Q2 2026, topline Q4 2026. 03/25/26:- PRECISE-AD 6-month assessments complete Q2 2026; blinded interim data early Q3 2026; topline early 2027; safety remains favorable. 05/12/26:- PRECISE-AD blinded 6-month interim analysis expected early Q3 2026; 12-month dosing completes year-end 2026; topline early 2027. 07/14/26:- Phase 1b blinded 6-month interim data expected in coming weeks. Topline unblinded results expected Early Q1 2027. 07/27/26:- PRECISE-AD Ph1b 6-month blinded interim data discussion set for July 28, 2026. 08/13/26:- PRECISE-AD reported positive blinded 6-month safety and biomarker data. Unblinded 12-month topline data will be reported in Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.